The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Cost-effectiveness of nivolumab vs. ipilimumab/nivolumab vs. trifluridine/tipiracil or mFOLFOX6/cetuximab for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer.
 
Jacqueline N. Chu
No Relationships to Disclose
 
Jin G. Choi
No Relationships to Disclose
 
Sassan Ostvar
No Relationships to Disclose
 
James Anthony Torchia
No Relationships to Disclose
 
Kerry Lynn Reynolds
No Relationships to Disclose
 
Justin F. Gainor
Honoraria - ARIAD; Incyte; Merck; Novartis; Pfizer
Consulting or Advisory Role - Amgen; Array BioPharma; Bristol-Myers Squibb; Genentech; Loxo; Takeda; Theravance
Research Funding - Adaptimmune (Inst); ARIAD; AstraZeneca (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Genentech; Jounce Therapeutics (Inst); Merck (Inst); Moderna Therapeutics (Inst); Novartis (Inst); Tesaro (Inst)
Travel, Accommodations, Expenses - Affymetrix
 
Daniel C. Chung
No Relationships to Disclose
 
Jeffrey W. Clark
Consulting or Advisory Role - Emas pharma
Research Funding - Pfizer (Inst)
 
Chin Hur
No Relationships to Disclose